Hypera

Working Capital Optimization And Neosaldina Launches Will Shape Future Operations

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

23 Mar 25

Updated

01 May 25

n/a

AnalystConsensusTarget's Fair Value

n/a

24.9%

-1.2%

24.9%

-1.2%

You can edit this narrative until May 12 6:02 AM. Then, changes will post as Updates.

Author's Valuation

R$29.5914.1% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates6

Shared on 01 May 25

Fair value Increased 31%

Shared on 23 Apr 25

Fair value Increased 1.03%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Increased 13%

AnalystConsensusTarget has increased future PE multiple from 9.4x to 10.6x.

Shared on 09 Apr 25

Fair value Decreased 12%

AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.

Shared on 02 Apr 25

Fair value Decreased 13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Decreased 7.22%

AnalystConsensusTarget has decreased revenue growth from 18.4% to 14.8% and decreased shares outstanding growth rate from -0.0% to -0.0%.

AnalystConsensusTarget Fair Value

R$29.59

14.1% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

14.01%

Pharma revenue growth rate

0.67%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

18.16%

Calculation

R$2.60b

Earnings '28

11.76x

PE Ratio '28

R$30.61b

Market Cap '28

R$30.61b

Market Cap '28

633.71m

No. shares '28

R$48.31

Share Price '28

R$48.31 Share Price '28

Discounted to 2025 @ 17.80% p.a.

R$29.55

Fair Value '25